Interim analyses: An update of an FDA reviewer's experience and perspective

Drug Information Journal

Volumn 33, Issue 1, 1999, Pages 165-176

  Sankoh, A J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Administrative interim analysis; Interim analysis for sample size adjustment; Multiple comparisons; Unplanned interim analysis

Indexed keywords

DRUG;

ARTICLE; DRUG INDUSTRY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; SAMPLE; STATISTICAL ANALYSIS;

EID: 0033004869     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159903300120     Document Type: Article

References (19)

1. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
2. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659-663.
3. Fleming TR, Harrington DP, O?Brien PC. Designs for group sequential tests. Control Clin Trials. 1984; 5:348-361.
4. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64: 191-199.
5. Pocock SJ. When to stop a clinical trial. Br Med J. 1992;405:235-240.
6. PMA Biostatistics and Medical Ad Hoc Committee on Interim Analysis. Interim analysis in the pharmaceutical industry. Control Clin Trials. 1993;14:160-173.
7. Lan KKG, Simon R, Halperin M. Stochastically curtailed tests in long-term clinical trials. Com Stat-Sequent Analy. 1982;1:207-219.
8. Roger JL, Berry DA. Group sequential clinical trials: a classical evaluation of Bayesian decision-theoretic designs. J Am Stat Assoc. 1994;1528-1534.
9. Emerson SS. Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach. Biometrics. 1995;51:1152-1162.
10. Grossman J, Parmar MKB, Spiegelhalter DJ, Freedman LS. A unified method for monitoring and analyzing controlled trials. Stat Med. 1994;13:1815-1826.
11. Herson J, Wittes J. The use of interim analysis for sample size adjustment. Drug Inf J. 1993;27:753-760.
12. Geller NL, Pocock SJ. Interim analyses in randomized clinical trials: Ramifications and guidelines for practioners. Biometrics. 1987;43:213-223.
13. Pocock SJ, Hughes MD. Practical problems in interim analyses with particular regard toestimation. Control Clin Trials. 1989;10:2095-2215.
14. Armitage P, McPherson CK, Rowe BC. Repeated significance tests on accumulatingdata. J Roy Stat Soc - series A. 1969; 132:235-244.
15. EaSt statistical software for group sequential clinical trials. Cytel Software Corporation, MA, USA.
16. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med. 1997;16:2529-2542.
17. Geller NL, Proschan MA, Follmann DA. Group sequential monitoring of multi-armed clinical trials. Drug Inf J. 1995;16:705-713.
18. Cui L, Hung HHJ, Wang S-J. Impact of changing sample size in a group sequential clinical trial. ASA Proceedings, Biopharm Section: 1997;52-57.
19. Heart Special Committee. Organization, review and administration of cooperative studies (Greenberg Report): A report from the Heart Special Project Committee to the National Advisory Council, May 1967. Control Clin Trials. 1988;1:137-148.